Evotec: patient biobank access to advance drug discovery

By Melissa Fassbender contact

- Last updated on GMT

The NURTuRE consortium will initially focus on chronic kidney disease and nephrotic syndrome patients. (Image: iStock/Natali_Mis)
The NURTuRE consortium will initially focus on chronic kidney disease and nephrotic syndrome patients. (Image: iStock/Natali_Mis)

Related tags: Kidney

Evotec has joined a consortium through which it gains access to a sample biobank in order to perform drug discovery based on unique kidney disease patient cohorts.

The National Unified Renal Translational Research Enterprise (NURTuRE) consortium is made up of UK-based academic institutions coordinated by Kidney Research UK and various industry partners.

NURTuRE is collecting clinical data at the UK Renal Registry and analyzing samples from 14 kidney disease centers across the UK over a five-year period. Through the consortium, researchers will be able to apply for access to patient samples, including kidney biopsies, blood, serum, and urine, which will be stored in the biobank for histological and molecular analysis to identify and validate targets and biomarkers.

Dr. Cord Dohrmann, CSO of Evotec told us the consortium gives the company access to patient data and samples “on the basis of fully established high-quality processes and databases​.”  

Protocols for sampling and analysis have been optimized to industry standard, he added.

Additionally, Dohman said the joint effort of academic experts and industry partners enables a comprehensive and unique core data analysis, which will be the basis for success of Evotec programs arising from NURTuRE data sets, he explained.

Evotec will expand and merge other R&D activities in the kidney disease field into NURTuRE, Dohrmann said, adding that this will bring “additional validation and accelerate the speed of these projects​.”

The biobank is funded by AbbVie Inc, Evotec, UCB Celltech Biopharma, and Kidney Research UK. 

Related news

Show more

Related products

show more

Liver Disease Capabilities

Liver Disease Capabilities

Q² Solutions | 01-Oct-2020 | Clinical Study

We integrate therapeutic insights, state-of-the-art technologies, best-in-class methods and quality systems to optimize NAFLD & NASH study design,...

CAR-T Cell Therapy

CAR-T Cell Therapy

Q² Solutions | 01-Sep-2020 | Clinical Study

Cell therapy involves the transfer of genetically altered cells into a patient. As a global central laboratory services organization, we provide testing...

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q² Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Related suppliers

Follow us


View more